NCT00765830已完成3 期
A 28 Week Extension to a 24 Week Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of Vildagliptin (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 349
- 试验地点
- 89
- 主要终点
- To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 52 weeks of treatment
研究概览
简要总结
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) when used in patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal insufficiency
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Complete the core study
排除标准
- •Did not comply with core study requirements
研究组 & 干预措施
1
Experimental
50mg qd vildagliptin
干预措施: vildagliptin (Drug)
2
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
To evaluate the safety and tolerability in patients with T2DM and moderate or severe renal insufficiency over 52 weeks of treatment
时间窗: 52 weeks
次要结局
- To explore the efficacy of vildagliptin (50 mg qd) versus placebo in patients with T2DM and moderate or severe renal insufficiency(52 weeks)
研究者
研究点 (89)
Loading locations...
相似试验
已完成
3 期
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)Renal InsufficiencyDiabetes Mellitus, Type 2NCT00770081Novartis75
已完成
3 期
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisMultiple SclerosisNCT00662649Novartis920
已完成
2 期
Long Term Study of Canakinumab (ACZ885) in Patients With GoutGouty ArthritisNCT00927810Novartis Pharmaceuticals341
终止
3 期
38 Week Extension Study to CAIN457C2303UveitisNCT01093846Novartis Pharmaceuticals59
撤回
3 期
Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious UveitisUveitisNCT01103024Novartis